GARTNER INC (IT) Stock News

Intapp's Celeste platform helps law firms control AI costs by routing simple queries to databases instead of expensive AI models, reducing token burn. The company's cloud migration strategy is driving 28% year-over-year ARR growth with 70%+ gross margins and strong free cash flow, positioning it as an efficient alternative to standard AI implementations that waste compute resources.

Candel Therapeutics announced that its phase 2 PrTK05 clinical trial data for aglatimagene besadenovec in localized prostate cancer has been accepted for poster presentation at the SITC 41st Annual Meeting in November 2026. The presentation will feature longitudinal immune-profiling, biodistribution, and viral shedding data from the trial combining aglatimagene with valacyclovir and radiation therapy.

Immunocore announced it will present Phase 1 data for brenetafusp combined with KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the 2026 SITC Annual Meeting. The presentation will showcase clinical data for the first combination of two T cell engagers in a solid tumor, with poster and oral sessions scheduled for November 6-7, 2026.

Addex Therapeutics announced the issuance of 93 million new registered shares at CHF 0.01 nominal value, fully subscribed by its wholly-owned subsidiary Addex Pharma S.A. The move increases issued share capital to CHF 3,116,544.96 while maintaining unchanged outstanding shares, designed to provide additional future financing flexibility for the clinical-stage biopharmaceutical company.

ITT is expected to report Q3 2026 earnings on November 4 with consensus estimates of $2.07 EPS (+16.3% YoY) and $1.41B revenue (+40.9% YoY). However, the company's Earnings ESP is -0.52%, indicating recent analyst pessimism, combined with a Zacks Rank #3, making it difficult to predict an earnings beat. Despite a strong historical track record of beating estimates, ITT does not appear to be a compelling earnings-beat candidate.

11:11 Systems highlights the strategic benefits of an integrated IT operational model for managing complex technology environments, reducing vendor complexity, and improving decision-making. The company also announced its eighth VMware-related acquisition, acquiring select enterprise customers from IBM's VMware Cloud Service Provider operations, strengthening its position as the largest private global VMware Cloud Service Provider partner.

Applied Industrial Technologies reported Q1 FY2026 revenue of $1.29 billion, up 7.6% year-over-year, slightly missing consensus estimates by 0.3%. EPS of $2.97 exceeded expectations by 3.85%, beating the $2.86 consensus. The Engineered Solutions segment showed strong growth at 14.1% YoY, while Service Center grew 4.2%. However, Service Center operating income fell short of estimates. The stock has underperformed the S&P 500 over the past month but maintains a Zacks Rank #2 (Buy) rating.

Illinois Tool Works (ITW) reported Q3 2026 EPS of $3.00, beating estimates, with revenues of $4.24 billion growing 4.4% year-over-year. Test & Measurement and Electronics surged 17.3%, while operating margin expanded 40 basis points. ITW raised full-year 2026 EPS guidance to $11.45-$11.55 and expects 4.5-5.5% revenue growth. Peer companies Graco missed estimates, while Dover and Allegion both beat expectations with strong organic growth.

Apple Hospitality REIT (APLE) has gained 5.81% over the past week and 11.68% over the past month, significantly outperforming its industry. The stock holds a Zacks Rank #2 (Buy) rating with a Momentum Style Score of A, supported by positive earnings estimate revisions and strong long-term performance of 56.07% over the past year.

The article compares two REIT ETFs: iShares Select U.S. REIT ETF (ICF), which concentrates on 30 large U.S. real estate companies, and iShares Global REIT ETF (REET), which diversifies across 317 global real estate stocks. While ICF has outperformed historically, REET is recommended as the better long-term buy due to its higher dividend yield (3.6% vs 2.7%), lower expense ratio (0.14% vs 0.32%), and broader diversification while maintaining substantial U.S. exposure.

Mortgage REITs AGNC Investment and Annaly Capital experienced sharp stock price declines of 16% and 18% respectively over three months as rising interest rates pressured bond values. Both companies saw their tangible book values drop significantly in Q3 2026—AGNC fell 17% to $7.13 per share and Annaly dropped 11% to $17.86 per share—highlighting the material risks of mREIT investing despite their attractive 16%+ dividend yields.

Vital Farms stock declined 2.08% to $8.95, underperforming the broader market gains. The company faces headwinds with projected Q3 EPS of -$0.14 (down 138.89% YoY) and revenue expected at $184.6 million (down 7.21% YoY). Analyst estimates have been revised downward by 10.35% in the past month, resulting in a Zacks Rank #4 (Sell) rating.

A securities class action lawsuit has been filed against Flotek Industries (NYSE: FTK) alleging the company made materially misleading statements about its $400 million PREPA power generation contract, which represented ~57% of its backlog. After Wolfpack Research published a report on August 17, 2026 alleging the contract was canceled, Flotek's stock declined sharply over three consecutive trading days, losing approximately 32% of its value. The court-ordered deadline for investors to seek lead plaintiff status is October 26, 2026.

A securities class action lawsuit has been filed against York Space Systems (NYSE: YSS) alleging the company made false statements about its satellite software functionality and failed to disclose risks to Pentagon contracts. The lawsuit covers investors who purchased securities during the January 2026 IPO and through May 11, 2026, when a critical report triggered a significant stock price decline. The deadline to seek lead plaintiff status is October 30, 2026.

Innventure faces a securities class action lawsuit alleging the company made false statements about Accelsius' DarkNX AI data center project and overstated 2026 revenue targets. After a May 2026 report exposed the project as fabricated, the stock fell 8.42%. In August 2026, Innventure suspended its revenue targets and disclosed the DarkNX project was removed from internal bookings, causing a 55% stock price decline. Investors who purchased securities between November 17, 2025 and August 13, 2026 may be eligible to participate in the lawsuit with an October 27, 2026 deadline to seek lead plaintiff status.

A securities class action lawsuit has been filed against Hyliion Holdings Corp. alleging that the company and its executives made false and misleading statements about business operations and engaged in insider trading. The lawsuit covers investors who purchased securities between May 12, 2026 and June 23, 2026. Following a critical report by Pelican Way Research on June 23, 2026, Hyliion's stock price fell 17.2% to $6.10 per share. The deadline to seek lead plaintiff status is October 27, 2026.

A securities class action lawsuit has been filed against XTI Aerospace (NASDAQ: XTIA) alleging that company executives made false and misleading statements about business operations while engaging in undisclosed activities. The lawsuit covers investors who purchased shares between April 15, 2026 and August 17, 2026. The alleged misconduct was revealed on August 17, 2026, when XTI Aerospace disclosed it could not timely file its Form 10-Q due to an internal review of its former CEO who resigned that day, resulting in a 15.9% stock price decline.

Annaly Capital and AGNC Investment are mortgage REITs offering yields above 16%, but both face significant risks from rising interest rates that have depressed their stock prices. While neither is suitable for traditional income investors due to volatile dividend histories, Annaly has a slight edge over AGNC due to its more diversified business model that includes mortgage servicing rights alongside mortgage securities.

Apple Hospitality REIT has been upgraded to a Zacks Rank #2 (Buy) rating due to rising earnings estimate revisions. The company is expected to earn $1.66 per share for fiscal year 2026, with consensus estimates increasing 1.9% over the past three months. The upgrade positions APLE in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation.

Rithm reported Q3 2026 revenue of $1.76 billion, up 58.9% year-over-year and beating the consensus estimate of $1.49 billion by 17.71%. EPS came in at $0.55, slightly above the $0.51 estimate. However, the stock carries a Zacks Rank #4 (Sell) rating and has underperformed the market, declining 4.8% over the past month.

Vital Farms (VITL) has attracted significant investor attention but faces headwinds with a Zacks Rank #4 (Sell) rating. The stock has declined 6.7% over the past month, underperforming the S&P 500. The company is expected to post losses for the current quarter and fiscal year, with negative earnings estimate revisions of -10.4% over the last 30 days. However, consensus estimates suggest a return to profitability next fiscal year with earnings of $0.11 per share.

Sika reported strong nine-month results with 4.8% sales growth in local currencies, reaching CHF 8.71 billion. The company improved its material margin to 55.4% and maintained EBITDA margin at 19.2%. Sika's Fast Forward cost-saving program is on track to deliver CHF 80 million in savings by 2026. The company completed acquisitions of Akkim and Azpects Group, and agreed to acquire Resonac Corporation's adhesives business. Sika confirmed its full-year 2026 guidance of 3-6% sales growth in local currencies.

Sika reported strong nine-month results with 4.8% sales growth in local currencies and CHF 8.71 billion in reported sales. The company increased its material margin to 55.4% and maintained an EBITDA margin of 19.2%. The Fast Forward program is on track to deliver CHF 80 million in benefits by 2026. Sika completed the Akkim acquisition, acquired Azpects Group in the UK, and agreed to acquire Resonac Corporation's adhesives business in Japan. The company reiterated its 2026 guidance of 3-6% local currency growth and 19.0-19.5% EBITDA margin.

Oculis announced new biomarker data from the Phase 2 ACUITY trial showing that Privosegtor reduced increases in neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in blood compared to placebo in optic neuritis patients. The data supports earlier findings of improved low-contrast visual acuity and retinal structure preservation, suggesting Privosegtor's neuroprotective effects. The company plans to continue the PIONEER registration program and explore applications in acute MS relapses.

Oculis announced Phase 2 ACUITY trial biomarker data showing Privosegtor reduced plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) levels compared to placebo in optic neuritis patients. The results provide objective evidence of reduced neuroaxonal injury and suppressed neuroinflammation, complementing previously reported functional improvements of +18-letter gains in low-contrast visual acuity and retinal preservation at Month 3. These findings support continued development of Privosegtor for acute optic neuritis and acute MS relapses.

Armour Residential REIT (ARR) reported quarterly earnings of $0.71 per share, missing the consensus estimate of $0.73, though it beat revenue expectations at $83.74 million. The stock has underperformed the S&P 500 by 41% year-to-date and carries a Zacks Rank #3 (Hold) rating. The REIT industry ranks in the bottom 18% of Zacks industries.

Roivant and Priovant announced positive Phase 3 results for brepocitinib in treating non-infectious uveitis. The drug met primary and secondary endpoints in both CLARITY-1 and CLARITY-2 trials, with 62% of patients achieving steroid-free quiescence at Week 48 compared to 20% on placebo. The companies plan to file a supplemental New Drug Application in the first half of 2027.

Class action law firm Monteverde & Associates PC is investigating four major merger and acquisition transactions to determine if shareholders are receiving fair deal terms. The investigations involve Utz Brands' sale to Intersnack Group, Safety Insurance Group's sale to Mapfre affiliate, Passage Bio's merger with Remix Therapeutics, and Finward Bancorp's sale to First Financial Bancorp.

Monteverde & Associates PC, a class action securities firm, is investigating four merger deals to determine if they represent fair value for shareholders: Bowman Consulting Group's sale to Bernhard Capital Partners ($43.00/share), DoubleVerify Holdings' sale to Nielsen Holdings ($13.60/share), Varex Imaging's sale to Teledyne Technologies ($18.90/share), and MarineMax's sale to Francisco Partners ($53.00/share). The firm is soliciting shareholders to evaluate whether these proposed transactions are fair.

Brodsky & Smith law firm is investigating four merger transactions to determine whether company boards breached fiduciary duties by failing to conduct fair processes and pay fair value to shareholders. The investigations involve Braze (being acquired by Salesforce for $47.50/share), ES Bancshares (acquired by Dime Commercial for $8.39/share), GoPro (acquired by Starman Optical for $1.14/share), and Bumble (acquired by Ithaca Holdings for $6.05/share).